carbapenems has been researched along with ro13-9904 in 33 studies
| Studies (carbapenems) | Trials (carbapenems) | Recent Studies (post-2010) (carbapenems) | Studies (ro13-9904) | Trials (ro13-9904) | Recent Studies (post-2010) (ro13-9904) |
|---|---|---|---|---|---|
| 7,355 | 147 | 5,277 | 6,815 | 798 | 2,755 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.03) | 18.7374 |
| 1990's | 6 (18.18) | 18.2507 |
| 2000's | 3 (9.09) | 29.6817 |
| 2010's | 13 (39.39) | 24.3611 |
| 2020's | 10 (30.30) | 2.80 |
| Authors | Studies |
|---|---|
| Dworkin, RJ; Kennedy, SL; Sachdeva, M; Sande, MA; Tureen, JH | 1 |
| Edwards, JR; Nairn, K; Shepherd, GL | 1 |
| Chmelik, V; Featherstone, A; Pfausler, B; Schmutzhard, E; Vukmirovits, G; Williams, KJ | 1 |
| Benali, K; Bingen, E; Bonacorsi, S; Doit, C; Fitoussi, F; Geslin, P | 1 |
| Verbist, L; Verhaegen, J | 1 |
| Cars, O; Löwdin, E; Odenholt, I | 1 |
| Manzor, O; Pawlak, J; Saravolatz, L | 1 |
| Anthony, L; Appelbaum, PC; Credito, K; Ednie, LM; Hoellman, DB; Jacobs, MR; Kelly, LM | 1 |
| Cravarezza, P; Donati, P; Franchino, L; Grassi, V; Pozzi, A; Prometti, P; Ravizzola, G; Romanelli, G; Zulli, R | 1 |
| Donskey, CJ; Pultz, NJ; Stiefel, U | 1 |
| Alış, EE; Cengiz, M; Ekici, S; Turan, G | 1 |
| Chau, F; Fantin, B; Le, P; Lefort, A; Lepeule, R; Massias, L; Nucci, A; Ruppé, E | 1 |
| Choi, SH; Chung, JW; Kim, MN; Kim, SH; Kim, YS; Lee, SO; Sung, H; Woo, JH | 1 |
| Apter, S; Eviatar, T; Grossman, E; Hoffman, C; Keller, N; Rosman, Y; Thaler, M | 1 |
| Bao, Y; Cai, Y; Chai, T; Gao, J; Li, X; Ma, R; Zhao, X; Zhou, Y | 1 |
| Hong, MT; Seifert, CF | 1 |
| Bethel, CR; Bonomo, RA; Doi, Y; Endimiani, A; Kasraian, S; Pires, J; Sendi, P; Taracila, M; Tinguely, R | 1 |
| Barnett, AG; Diab, S; Fraser, JF; Fung, YL; Roberts, JA; Shekar, K; Wallis, SC | 1 |
| Fisher, K; Juang, P; Kollef, MH; Micek, ST; Trupka, T | 1 |
| Chen, SL; Heng, ST; Lye, DC; Ng, TM; Wong, JGX | 1 |
| Almirante, B; Escolà-Vergé, L; González-López, JJ; Larrosa, N; Len, O; Los-Arcos, I; Pigrau, C; Viñado, B | 1 |
| Murray, BE; Singh, KV | 1 |
| Azougagh, K; Barbier, F; Boulain, T; Boutrot, M; Guinard, J | 1 |
| Harris, PNA; Henderson, A; Paterson, DL | 1 |
| Maquieira, Á; Morais, S; Peña-Mendizabal, E | 1 |
| Cisera, K; Hughes, C; Rogers, B; Taylor, L; Xie, O | 1 |
| Asai, N; Hagihara, M; Kato, H; Koizumi, Y; Mikamo, H; Ohashi, W; Sakanashi, D; Shibata, Y; Shiota, A; Suematsu, H; Watanabe, H; Yamagishi, Y | 1 |
| Akeda, Y; Arakawa, Y; Minoura, K; Miyamoto, K; Onda, M; Shoji, M; Tomono, K; Tsuchiya, T; Yamabe, K | 1 |
| Cerboni, G; Corsica, G; De Luca, F; Docquier, JD; Galleni, M; Gavara, L; Hadjadj, M; Hernandez, JF; Legru, A; Licznar-Fajardo, P; Nauton, L; Sandra Mercuri, P; Sannio, F; Sevaille, L; Verdirosa, F; Vo Hoang, Y | 1 |
| Abdulhemid Said, L; Muhsin, EA; Sajid Al-Jubori, S | 1 |
| Chen, L; He, XP; Hong, SJ; Hua, J; Jing, RC; Luo, XY; Xue, HW; Yuan, CY; Yue, Y | 1 |
| Ho, HC; Huang, C; Li, W; Liu, C; Shi, L; Xia, H; Yang, L; Yang, X; Zeng, Y; Zhang, W | 1 |
| Ayodo, C; Bollinger, S; Call, DR; Caudell, MA; Ita, T; Kariuki, S; Luvsansharav, U; Mugoh, R; Omulo, S; Palmer, GH; Ramay, BM; Smith, RM; Styczynski, A | 1 |
1 review(s) available for carbapenems and ro13-9904
| Article | Year |
|---|---|
Current evidence for therapy of ceftriaxone-resistant Gram-negative bacteremia.
Topics: Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftriaxone; Cephalosporin Resistance; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Randomized Controlled Trials as Topic | 2020 |
2 trial(s) available for carbapenems and ro13-9904
| Article | Year |
|---|---|
A randomised comparison of meropenem with cefotaxime or ceftriaxone for the treatment of bacterial meningitis in adults. Meropenem Meningitis Study Group.
Topics: Adult; Carbapenems; Cefotaxime; Ceftriaxone; Humans; Meningitis, Bacterial; Meropenem; Thienamycins; Treatment Outcome | 1995 |
Carbapenems in the treatment of severe community-acquired pneumonia in hospitalized elderly patients: a comparative study against standard therapy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Clarithromycin; Community-Acquired Infections; Costs and Cost Analysis; Drug Combinations; Drug Costs; Drug Therapy, Combination; Female; Hospitalization; Humans; Imipenem; Male; Meropenem; Pneumonia, Bacterial; Prospective Studies; Thienamycins; Treatment Outcome | 2002 |
30 other study(ies) available for carbapenems and ro13-9904
| Article | Year |
|---|---|
Evaluation of FCE 22101 in experimental meningitis caused by Escherichia coli and Streptococcus pneumoniae.
Topics: Animals; Anti-Bacterial Agents; Blood Bactericidal Activity; Carbapenems; Ceftriaxone; Escherichia coli Infections; Imipenem; Meningitis; Meningitis, Pneumococcal; Microbial Sensitivity Tests; Penicillins; Rabbits | 1989 |
Efficacy of meropenem in experimental meningitis.
Topics: Ampicillin; Animals; Carbapenems; Ceftazidime; Ceftriaxone; Cephalosporins; Cerebrospinal Fluid; Cerebrospinal Fluid Proteins; Drug Evaluation; Drug Resistance, Microbial; Escherichia coli Infections; Gentamicins; Guinea Pigs; Haemophilus Infections; Haemophilus influenzae; Listeriosis; Meningitis, Bacterial; Meropenem; Neisseria meningitidis; Penicillin G; Pneumococcal Infections; Thienamycins | 1995 |
Comparative in vitro killing activities of meropenem, imipenem, ceftriaxone, and ceftriaxone plus vancomycin at clinically achievable cerebrospinal fluid concentrations against penicillin-resistant Streptococcus pneumoniae isolates from children with meni
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Cephalosporins; Child; Drug Therapy, Combination; Humans; Imipenem; Meningitis, Pneumococcal; Meropenem; Microbial Sensitivity Tests; Penicillin Resistance; Streptococcus pneumoniae; Thienamycins; Vancomycin | 1998 |
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Topics: Amoxicillin; Ampicillin; Anti-Bacterial Agents; beta-Lactams; Carbapenems; Cefaclor; Cefadroxil; Cefatrizine; Cefepime; Cefixime; Cefotaxime; Cefpirome; Cefpodoxime; Ceftazidime; Ceftibuten; Ceftizoxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cephradine; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Microbial Sensitivity Tests; Penicillin Resistance; Penicillins; Piperacillin; Pneumococcal Infections; Serotyping; Species Specificity; Streptococcus pneumoniae | 1998 |
In vitro pharmacodynamic studies of L-749,345 in comparison with imipenem and ceftriaxone against gram-positive and gram-negative bacteria.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Gram-Negative Bacteria; Gram-Positive Bacteria; Imipenem; Methicillin Resistance; Microbial Sensitivity Tests | 1998 |
In-vitro activity of 29 antimicrobial agents against penicillin-resistant and -intermediate isolates of Streptococcus pneumoniae.
Topics: Anti-Bacterial Agents; Carbapenems; Cefotaxime; Ceftriaxone; Cephalosporins; Drug Resistance, Multiple; Glycopeptides; Macrolides; Microbial Sensitivity Tests; Penicillin Resistance; Quinolones; Streptococcus pneumoniae | 1999 |
In vitro antianaerobic activity of ertapenem (MK-0826) compared to seven other compounds.
Topics: Bacteria, Anaerobic; Carbapenems; Ceftriaxone; Cephalosporins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Thienamycins | 2002 |
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.
Topics: Animals; beta-Lactams; Carbapenems; Ceftriaxone; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Enterococcus; Ertapenem; Female; Imipenem; Intestines; Klebsiella pneumoniae; Mice; Piperacillin; Sodium Chloride; Time Factors; Vancomycin Resistance | 2007 |
Fluoroquinolone-resistant acute prostatitis requiring hospitalization after transrectal prostate biopsy: effect of previous fluoroquinolone use as prophylaxis or long-term treatment.
Topics: Aged; Anti-Bacterial Agents; Anti-Infective Agents; Antibiotic Prophylaxis; Biopsy; Carbapenems; Ceftriaxone; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Enterococcus; Escherichia coli; Escherichia coli Infections; Fluoroquinolones; Hospitalization; Humans; Length of Stay; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatitis; Retrospective Studies; Vancomycin | 2012 |
Cefoxitin as an alternative to carbapenems in a murine model of urinary tract infection due to Escherichia coli harboring CTX-M-15-type extended-spectrum β-lactamase.
Topics: Animals; Anti-Bacterial Agents; Bacterial Load; beta-Lactamases; beta-Lactams; Carbapenems; Cefoxitin; Ceftriaxone; Conjugation, Genetic; Disease Models, Animal; Drug Administration Schedule; Ertapenem; Escherichia coli; Escherichia coli Infections; Female; Humans; Imipenem; Kidney; Mice; Microbial Sensitivity Tests; Mutation Rate; Plasmids; Urinary Bladder; Urinary Tract Infections | 2012 |
Impact of penicillin nonsusceptibility on clinical outcomes of patients with nonmeningeal Streptococcus pneumoniae bacteremia in the era of the 2008 clinical and laboratory standards institute penicillin breakpoints.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Child; Child, Preschool; Female; Humans; Infant; Length of Stay; Male; Middle Aged; Penicillin Resistance; Penicillins; Pneumococcal Infections; Retrospective Studies; Streptococcus pneumoniae; Survival Rate; Treatment Outcome; Vancomycin | 2012 |
Nocardiosis: a 15-year experience in a tertiary medical center in Israel.
Topics: Adrenal Cortex Hormones; Adult; Aged; Amikacin; Carbapenems; Ceftriaxone; Cohort Studies; Encephalitis; Female; Humans; Immunocompromised Host; Israel; Male; Middle Aged; Nocardia Infections; Pleuropneumonia; Retrospective Studies; Risk Factors; Skin Diseases, Bacterial; Soft Tissue Infections; Tertiary Care Centers; Treatment Outcome; Trimethoprim, Sulfamethoxazole Drug Combination | 2013 |
Antibiotic resistance and OXA-type carbapenemases-encoding genes in airborne Acinetobacter baumannii isolated from burn wards.
Topics: Acinetobacter baumannii; Air Microbiology; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Burn Units; Carbapenems; Cefoperazone; Ceftriaxone; Ciprofloxacin; DNA, Bacterial; Drug Resistance, Multiple, Bacterial; Humans; Imipenem; Microbial Sensitivity Tests; Polymerase Chain Reaction; Repetitive Sequences, Nucleic Acid; Sulbactam | 2014 |
Clinical Impact of Discordant Prescribing of Fluoroquinolones and Alternative Treatments in Escherichia coli Pyelonephritis.
Topics: Adult; Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Drug Resistance, Bacterial; Escherichia coli Infections; Female; Fluoroquinolones; Guidelines as Topic; Humans; Length of Stay; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pyelonephritis; Retrospective Studies; Treatment Outcome | 2016 |
In Vivo Evolution of CMY-2 to CMY-33 β-Lactamase in Escherichia coli Sequence Type 131: Characterization of an Acquired Extended-Spectrum AmpC Conferring Resistance to Cefepime.
Topics: Aged; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefepime; Ceftriaxone; Cephalosporins; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Escherichia coli Proteins; Humans; Male; Microbial Sensitivity Tests; Molecular Docking Simulation | 2015 |
Can physicochemical properties of antimicrobials be used to predict their pharmacokinetics during extracorporeal membrane oxygenation? Illustrative data from ovine models.
Topics: Animals; Anti-Infective Agents; Carbapenems; Caspofungin; Ceftriaxone; Ciprofloxacin; Critical Illness; Doripenem; Echinocandins; Extracorporeal Membrane Oxygenation; Fluconazole; Gentamicins; Lipopeptides; Meropenem; Models, Theoretical; Sheep; Sheep, Domestic; Thienamycins; Vancomycin | 2015 |
Enhanced antimicrobial de-escalation for pneumonia in mechanically ventilated patients: a cross-over study.
Topics: Academic Medical Centers; Aged; Anti-Bacterial Agents; Carbapenems; Cefepime; Ceftriaxone; Cephalosporins; Cross-Over Studies; Female; Hospital Mortality; Humans; Intensive Care Units; Male; Middle Aged; Monobactams; Pneumonia; Pneumonia, Ventilator-Associated; Prospective Studies; Quinolones; Respiration, Artificial; Statistics, Nonparametric | 2017 |
No association between resistance mutations, empiric antibiotic, and mortality in ceftriaxone-resistant Escherichia coli and Klebsiella pneumoniae bacteremia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamases; Carbapenems; Ceftriaxone; Cephalosporins; Drug Resistance, Bacterial; Escherichia coli; Female; Genes, Bacterial; Humans; Klebsiella pneumoniae; Male; Mutation; Phylogeny; Virulence; Virulence Factors | 2018 |
Infections by OXA-48-like-producing Klebsiella pneumoniae non-co-producing extended-spectrum beta-lactamase: Can they be successfully treated with cephalosporins?
Topics: Aged; Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cefepime; Ceftriaxone; Cephalosporins; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Male; Middle Aged; Nephritis; Retrospective Studies; Spain | 2019 |
Loss of a Major Enterococcal Polysaccharide Antigen (Epa) by
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Enterococcus faecalis; Gram-Positive Bacterial Infections; Microbial Sensitivity Tests; Polysaccharides | 2019 |
Antibiotics with activity against intestinal anaerobes and the hazard of acquired colonization with ceftriaxone-resistant Gram-negative pathogens in ICU patients: a propensity score-based analysis.
Topics: Aged; Anti-Bacterial Agents; Bacteria, Anaerobic; Carbapenems; Ceftriaxone; Cross Infection; Drug Resistance, Bacterial; Female; Gram-Negative Bacteria; Gram-Negative Bacterial Infections; Humans; Imipenem; Intensive Care Units; Intestines; Male; Meropenem; Middle Aged; Propensity Score; Retrospective Studies | 2019 |
Neo-antigens for the serological diagnosis of IgE-mediated drug allergic reactions to antibiotics cephalosporin, carbapenem and monobactam.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactams; Carbapenems; Cefotaxime; Ceftriaxone; Cefuroxime; Cephalosporins; Cross Reactions; Drug Hypersensitivity; Humans; Immunoglobulin E; Immunoglobulin G; Meropenem; Monobactams; Penicillins; Skin Tests | 2020 |
Clinical syndromes and treatment location predict utility of carbapenem sparing therapies in ceftriaxone-non-susceptible Escherichia coli bloodstream infection.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Azabicyclo Compounds; Bacteremia; Carbapenems; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Combinations; Drug Resistance, Multiple, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Tazobactam | 2020 |
Ceftriaxone versus tazobactam/piperacillin and carbapenems in the treatment of aspiration pneumonia: A propensity score matching analysis.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Aspiration; Propensity Score; Retrospective Studies | 2021 |
Enhancement of Acinetobacter baumannii biofilm growth by cephem antibiotics via enrichment of protein and extracellular DNA in the biofilm matrices.
Topics: Acinetobacter baumannii; Anti-Bacterial Agents; Carbapenems; Ceftazidime; Ceftriaxone; DNA; Extracellular Polymeric Substance Matrix | 2022 |
1,2,4-Triazole-3-thione analogues with an arylakyl group at position 4 as metallo-β-lactamase inhibitors.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; Carbapenems; Ceftazidime; Ceftriaxone; Ethylenes; HeLa Cells; Humans; Ligands; Meropenem; Microbial Sensitivity Tests; Thiones; Triazoles; Zinc | 2022 |
Prevalence of Efflux Pump and Porin-Related Antimicrobial Resistance in Clinical
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Carbapenems; Cefazolin; Cefepime; Cefoxitin; Ceftazidime; Ceftriaxone; Cephalosporins; Drug Resistance, Bacterial; Ertapenem; Humans; Imipenem; Iraq; Klebsiella pneumoniae; Microbial Sensitivity Tests; Porins; Prevalence | 2022 |
Comparison of the relative efficacy of β-lactam/β-lactamase inhibitors and carbapenems in the treatment of complicated urinary tract infections caused by ceftriaxone-non-susceptible Enterobacterales: a multicentre retrospective observational cohort study.
Topics: Anti-Bacterial Agents; beta-Lactamase Inhibitors; beta-Lactamases; beta-Lactams; Carbapenems; Ceftriaxone; Enterobacteriaceae; Enterobacteriaceae Infections; Gammaproteobacteria; Humans; Lactams; Retrospective Studies; Urinary Tract Infections | 2023 |
Estimating the effect of increasing ambient temperature on antimicrobial resistance in China: A nationwide ecological study with the difference-in-differences approach.
Topics: Anti-Bacterial Agents; Carbapenems; Cefotaxime; Ceftriaxone; Drug Resistance, Bacterial; Escherichia coli; Microbial Sensitivity Tests; Quinolones; Temperature | 2023 |
Risk Factors for Colonization With Extended-Spectrum Cephalosporin-Resistant and Carbapenem-Resistant Enterobacterales Among Hospitalized Patients in Kenya: An Antibiotic Resistance in Communities and Hospitals (ARCH) Study.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftriaxone; Cephalosporins; Cross-Sectional Studies; Drug Resistance, Microbial; Hospitals; Humans; Kenya; Monobactams; Risk Factors | 2023 |